3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
23
pembrolizumab
22
Paclitaxel
17
Specimen Handling
14
Magnetic Resonance Spectroscopy
11
Cyclophosphamide
10
Biopsy
9
Taxes
7
Capecitabine
7
130-nm albumin-bound paclitaxel
6
sacituzumab govitecan
5
Nivolumab
5
Gemcitabine
5
Doxorubicin
5
Albumin-Bound Paclitaxel
5
olaparib
3
fludarabine
3
eribulin
3
durvalumab
3
atezolizumab
3
Letrozole
3
Fulvestrant
3
Epirubicin
3
Bevacizumab
3
veliparib
2
poly ICLC
2
pertuzumab
2
aldesleukin
2
abemaciclib
2
Trastuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
famitinib
×
30 days
×
Clear all
NCT05582499
2026-05-28
FASCINATE-N
Fudan University
Phase 2
Recruiting
716 enrolled